Female with PCOS experiences receding and thinning hair, wants dutasteride instead of spironolactone. Discusses desire to reduce DHT without losing libido.
Disinfecting microneedlers is important to prevent infection, with suggestions to use high-percentage alcohol or denture tablets for sterilization. Rollers may cause skin damage, so stamps or pens are recommended for safer microneedling.
A 35-year-old is experiencing continued hair shedding despite using Finasteride, 2% Ketoconazole shampoo, and dermarolling. They plan to ask their doctor about adding oral Minoxidil and possibly switching to Dutasteride.
The conversation discusses a new model for understanding androgenetic alopecia (AGA), linking it to dietary and lifestyle factors similar to PCOS, and highlighting the role of DHT, vascular damage, and inflammation. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The user is concerned about high prolactin levels and low testosterone levels after stopping finasteride for three weeks. They are considering resuming finasteride but are worried it might further increase prolactin levels.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
The conversation discusses a personal theory on the role of DHT in stress and reproduction, suggesting it converts testosterone for reproductive traits. The discussion includes skepticism and mentions individual differences in physiology and neurochemistry.
The user experienced side effects like shallow breathing, loss of libido, and erectile issues after using topical finasteride with minoxidil for hair loss. They are considering whether to continue the treatment despite these side effects.
A user with seborrheic dermatitis uses Ketoconazole 2% and Betamethasone and is considering starting Minoxidil for thinning hair. They are concerned about using Minoxidil and Betamethasone simultaneously.
The conversation discusses the use of 5-alpha-reductase inhibitors like finasteride and dutasteride for hair loss in transgender women, particularly in relation to testosterone suppression. The original poster has been using dutasteride and is considering stopping it due to undetectable testosterone levels.
A 16 year old's experience with using pyrilutamide to treat hair loss, and the potential side effects of adding tretinoin to minoxidil and finasteride treatments.
The user has been using a hair loss treatment regimen including RU58841, minoxidil, and dutasteride, but still experiences hairline recession and fatigue despite high testosterone levels. They are considering adjusting their dutasteride dosage due to concerns about libido and energy levels.
Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.
User experienced scarring from microneedling at fast speed and paused treatment for 3-4 weeks to recover. Advice given includes waiting a full month for recovery to avoid scars.
The user switched from finasteride to 2.5 mg dutasteride daily and added 1% pyrilutamide to address persistent scalp itch, but the itch remains. They also use 2% ketoconazole and 2.5% selenium sulfide shampoo for temporary relief.
Theo Von discussed undergoing a hair transplant and is reportedly using finasteride. Joe Rogan also had hair transplants but faced challenges due to thin donor areas and not using finasteride.
The user experienced persistent acne and skin issues with dutasteride, leading them to stop its use. They switched to finasteride, which caused mild acne and potential liver concerns, prompting consideration of alternative treatments like topical finasteride and GHK-Cu.
The user has been using pyrilutamide 0.5% for over 7 weeks, alongside dutasteride, and noticed some hair improvement, particularly at the temples. They plan to continue and possibly try a 1% solution, with no shedding or side effects reported.
Elevated bile acids can inhibit the enzyme AKR1C2, leading to increased DHT levels, which may accelerate hair loss in those predisposed to androgenetic alopecia. Treatments mentioned include topical minoxidil and finasteride.
Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.
The user has been using finasteride and dutasteride mesotherapy for 2 months with no noticeable change in hair loss or shedding. They experienced side effects from oral minoxidil and suspect seborrheic dermatitis.
The conversation discusses hair loss and the potential impact of zinc supplementation, with some users suggesting it might contribute to shedding. The original poster is using finasteride and considering adjusting their zinc intake and dosage of finasteride.
The post discusses the user's experience with hair loss treatment using finasteride, clobetasol propionate, and ketoconazole shampoo. The conversation warns about the potential side effects of clobetasol, a powerful topical steroid, and emphasizes its short-term usage.
The post discusses using 2% ketoconazole shampoo as a competitive androgen receptor antagonist for hair loss, applied for 1.5 hours daily. The user questions its effectiveness and potential benefits compared to finasteride and minoxidil.
The user experienced microinflammation on the crown after using mometasone furoate (Nasonex) nasal spray. They are seeking information on the relationship between this corticosteroid and hair loss.
A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.
Being overweight may increase finasteride side effects due to higher aromatase activity converting testosterone to estradiol. Maintaining a healthy weight could reduce these side effects.
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.